thought ceo chang posit nice ahead
next leg growth buy
spoke management appreci investor worri nervou energi stock
vs biotech ceo chang w/ known mix result
 co quit confid transit next leg growth time posit ahead
mani drug pipelin beyond cf come view chang neutral
thesi lot pipelin mo like stock pullback lower
end rang
tee next leg pipelin top-lin growth go
effect april reshma kewalramani succeed jeffrey leiden new ceo
jeff serv execut chairman henc involv w/ mani on-going
project convers far today suggest investor feel uncertainti sinc
recent biotech ceo transit signal top busi get tougher
ahead legaci leader want transit ahead howev jeff assur
us compani never stronger spent year work w/ reshma
feel confid well prepar posit want announc
news well advanc give investor time month get know reshma
alreadi get familiar w/ street conf call investor meet
opposit transit search put investor limbo
went void period search underway
know reshma transit sinc reshma
built medic team led develop cf tripl led fast
advanc phase nda record year addit met
criteria board desir intern candid physician-scientist
align co dna investor feedback alreadi good
last mo particularli cf tripl program big
success led reshma jeff help transit also take sever key
respons chairman engag on-going key busi develop given
deal-mak experi overse new genet therapi program
new genet research hub boston start exon crispr on-going work
w/ investor relat lead govern polit affair state feder
intern level
prep ie vision next year growth year
new data set earli stage whether head right direct board
develop plan ensur growth period past cf
cf tripl provid amaz revenu growth intern
pipelin drive growth thereaft confid investor look forward next
month report phase i/ii data sever pipelin candid
beta-th scd fsg -- upsid thesi stock investor
buy ahead note asset clinic across non-cf
diseas one asset year ago
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
global biotechnolog compani focus develop small molecul drug seriou unmet
diseas compani previous develop drug fda approv hiv hep approv drug
kalydeco orkambi treatment variou mutat cystic fibrosi vertex develop pipelin addit cf
drug popul unaddress current drug addit compani build pipelin beyond cf next
year vertex aspir becom fulli integr biopharmaceut compani discoveri commerci compani
run global sale market commerci infrastructur
pt base probability-bas dcf risk competit clinic trial data
pt base ep also probability-adjust dcf risk includ pipelin disappointments/success
pt base pipeline-adjust dcf multipl ep estim risk competit pipelin disappoint
michael yee certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
andrew tsai certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
kelechi chiker ph certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
arshad haider certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
jefferi llc act financi advisor kite pharma kite sale compani
jefferi group llc make market secur adr vertex pharmaceut incorpor
jefferi group llc make market secur adr biogen inc
jefferi group llc make market secur adr inc
pleas see import disclosur inform page report
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
rate price target histori vertex pharmaceut incorpor
rate price target histori biogen inc
jefferi llc act financi advisor nightstar therapeut plc announc acquisit biogen inc
rate price target histori inc
jefferi llc act financi advisor kite pharma kite sale compani
note box rate price target histori chart repres action past three year analyst
initi compani made chang rate price target compani discontinu coverag compani
pleas see import disclosur inform page report
